TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02483455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2014-ALC-919-US
Description: A topical solution to be applied twice daily for the treatment of Common Warts

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle-Control Topical Solution
Description: A topical solution to be applied twice daily for the treatment of Common Warts
Study: NCT03911869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: taken orally
Study: NCT00648648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine administered at 1000 mg/m\^2 by IV infusion in a 28-day cycle.
Study: NCT03911869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: taken orally
Study: NCT01632072

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional support
Description: Nutritional support and counseling
Study: NCT00789295

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet and Low-Carbohydrates diet
Description: The Mediterranean diet: relatively rich in Carbohydrate(52% of the total daily energy intake), rich in dietary fibre (28g/1000 kcal both of soluble and unsoluble types) and with a low glycemic index (51%) versus Low-carbohydrates diet : diet rich in MUFA (23%), relatively low in CHO (45%), low in dietary fibre (8g/1000 kcal) and with a relatively high glycemic index (87%)for 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet and Low-Carbohydrates diet
Description: The Mediterranean diet: relatively rich in Carbohydrate(52% of the total daily energy intake), rich in dietary fibre (28g/1000 kcal both of soluble and unsoluble types) and with a low glycemic index (51%) versus Low-carbohydrates diet : diet rich in MUFA (23%), relatively low in CHO (45%), low in dietary fibre (8g/1000 kcal) and with a relatively high glycemic index (87%)for 4 weeks
Study: NCT02209038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded AD Choice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Life-sustaining Therapy Choice
Study: NCT00648648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine administered at 1000 mg/m\^2 by IV infusion in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine administered at 1000 mg/m\^2 by IV infusion in a 28-day cycle.
Study: NCT00079820

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACAM3000 MVA Vaccine
Description: Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACAM3000 MVA Vaccine
Description: Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days
Study: NCT02932579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxycontin/acetominophen
Description: hydroxycontin 2.5 mg, acetominophen 325 mg
Study: NCT00079820

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ACAM3000 MVA Vaccine
Description: Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACAM3000 MVA Vaccine
Description: Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACAM3000 MVA Vaccine
Description: Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days
Study: NCT02682160

Intervention type: OTHER
Group type: OTHER
Intervention: use of Protein Assistant
Description: The patient has to complete a dietary record every 2 weeks during 2 months (month 2 and 3 after surgery). The aim is to intake 60g per day. If the aim is not reached, Protein assistant suggests qualitative and/or quantitative solutions.
Study: NCT02574819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (MNTX)
Description: MNTX nearly 0.15mg/kg administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
Study: NCT00648648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin administered at 75 mg/m\^2 by IV infusion in a 21-day cycle.
Study: NCT02574819

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
Study: NCT03147599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coloverin
Description: Mebeverine hydrochloride 135 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02971527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oste-scan 500A
Description: The investigators will detect the same calcaneus of each subject by experimental ultrasound bone strength device. Experimental ultrasound bone strength device's model number is Oste-scan 500A and report number is Z-Y-2009-2014, Z-E-0530-2014(G).
Study: NCT02971527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oste-scan 500A
Description: The investigators will detect the same calcaneus of each subject by experimental ultrasound bone strength device. Experimental ultrasound bone strength device's model number is Oste-scan 500A and report number is Z-Y-2009-2014, Z-E-0530-2014(G).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SONOST3000
Description: The investigators will detect the same calcaneus of each subject by control ultrasound bone strength device. Control ultrasound bone strength device's model number is SONOST3000.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SONOST3000
Description: The investigators will detect the same calcaneus of each subject by control ultrasound bone strength device. Control ultrasound bone strength device's model number is SONOST3000.
Study: NCT05267418

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automated nasal O2 titration with FreeO2
Description: The participant received, in a randomized, cross-over study design: 1) automated nasal oxygen titration administered by a closed loop system (FreeO2) alone, 2) or with high flow nasal therapy (Airvo2) set at 60 liters per minute with nasal canula, or 3) oxygen by nasal canula at a fixed flow of 2 liters per minute during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automated nasal O2 titration with FreeO2
Description: The participant received, in a randomized, cross-over study design: 1) automated nasal oxygen titration administered by a closed loop system (FreeO2) alone, 2) or with high flow nasal therapy (Airvo2) set at 60 liters per minute with nasal canula, or 3) oxygen by nasal canula at a fixed flow of 2 liters per minute during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automated nasal O2 titration with FreeO2
Description: The participant received, in a randomized, cross-over study design: 1) automated nasal oxygen titration administered by a closed loop system (FreeO2) alone, 2) or with high flow nasal therapy (Airvo2) set at 60 liters per minute with nasal canula, or 3) oxygen by nasal canula at a fixed flow of 2 liters per minute during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT)
Study: NCT04516655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide combined with rituximab and high-dose methotrexate
Description: chidamide 20 mg biw PO day1-14 and rituximab 375 mg/m2 IV given on day 1 and methotrexate 3.5g/m2 IV given on day 2 of every 21-day cycle for 6 cycles in untreated patients with primary central nervous system lymphoma
Study: NCT01422772

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202RY
Description: 0.5mg intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202RY
Description: 1mg intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202RY
Description: 2mg intramuscular injection
Study: NCT03512470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sistema Prevena ™(TVAC)
Description: The medications with a negative topical pressure system (Sistema Prevena ™) will be applied directly in the Operating Room. Thereafter medication will be checked in the inpatient ward after 48 h from the intervention, evaluating the possible absorption of exudate on the surface. If no absorption are detected within 48 hours, the medication won't be removed and renewed in the 7th day (± 2 days) post-operative; and to follow every 7 (± 2 days) until the points are removed. If the wound continues to progress towards recovery, the protocol will continue until discharge and / or rehabilitation and / or surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medication
Description: standard medication in use (sterile gauze and TNT patch or medicated patches).
Study: NCT01105780

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-41443532
Description: 250mg tablet once daily for 1 day
Study: NCT00102934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide-intensified HAART
Description: 90 mg tablet taken orally twice daily
Study: NCT00695513

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BENEO synergy1
Description: 50/50 v/v inulin/oligofructose 10 gram BID
Study: NCT00550277

Intervention type: DRUG
Group type: OTHER
Intervention: LBH589
Description: LBHLBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly). To enable patients to undergo cardiac monitoring (Section 3.5.2), all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles.
Study: NCT01320969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction course
Description: an eight-week mindfulness-based stress reduction course
Study: NCT01929707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3050258

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00631618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutent (sunitinib)
Description: The initial dose will be 50mg daily taken for 4 consecutive weeks followed by 2-weeks off to comprise a complete cycle of 6 weeks.
Study: NCT02445703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Hepatitis A vaccine (HAV)
Description: Dosage of HAV is 250u hepatitis A antigen/0.5ml/dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Hepatitis A vaccine (HAV)
Description: Dosage of HAV is 250u hepatitis A antigen/0.5ml/dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and hepatitis B vaccine (HABV)
Description: Dosage of HABV is 250u hepatitis A antigen and 5µg hepatitis B antigen/0.5ml/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and hepatitis B vaccine (HABV)
Description: Dosage of HABV is 250u hepatitis A antigen and 5µg hepatitis B antigen/0.5ml/dose
Study: NCT02551913

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: the adolescents will not receive any specific intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: A theory based sleep hygiene intervention based on the theory planned behavior will be conduced on the adolescent
Study: NCT01213290

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS - FNA with stylet
Description: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) with stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)
Description: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)without stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
Study: NCT03616262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox + Lidocaine
Description: The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox + Lidocaine
Description: The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine alone
Description: The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine alone
Description: The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
Study: NCT01496274

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rIX-FP
Description: Recombinant IX-FP (rIX-FP) is a fusion protein linking coagulation factor IX with albumin, and will be administered by intravenous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rIX-FP
Description: Recombinant IX-FP (rIX-FP) is a fusion protein linking coagulation factor IX with albumin, and will be administered by intravenous administration
Study: NCT02898142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postprandial test
Description: Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting. This post prandial test is the same in the two study groups.
Study: NCT00648648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin administered at 75 mg/m\^2 by IV infusion in a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin administered at 75 mg/m\^2 by IV infusion in a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin administered at 75 mg/m\^2 by IV infusion in a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin administered at 75 mg/m\^2 by IV infusion in a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin administered at 75 mg/m\^2 by IV infusion in a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin administered at AUC/time curve of 5 mg/min/mL (AUC5) by IV infusion in a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin administered at AUC/time curve of 5 mg/min/mL (AUC5) by IV infusion in a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin administered at AUC/time curve of 5 mg/min/mL (AUC5) by IV infusion in a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin administered at AUC/time curve of 5 mg/min/mL (AUC5) by IV infusion in a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin administered at AUC/time curve of 5 mg/min/mL (AUC5) by IV infusion in a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin administered at AUC/time curve of 5 mg/min/mL (AUC5) by IV infusion in a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin administered at AUC/time curve of 5 mg/min/mL (AUC5) by IV infusion in a 21-day cycle.
Study: NCT04253210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychological
Description: Participants will either view body positive images that are sexualized (vs. nonsexualized) and a great deal of evidence of photo modification (vs. low photo modification).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychological
Description: Participants will either view body positive images that are sexualized (vs. nonsexualized) and a great deal of evidence of photo modification (vs. low photo modification).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychological
Description: Participants will either view body positive images that are sexualized (vs. nonsexualized) and a great deal of evidence of photo modification (vs. low photo modification).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychological
Description: Participants will either view body positive images that are sexualized (vs. nonsexualized) and a great deal of evidence of photo modification (vs. low photo modification).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychological
Description: Participants will either view body positive images that are sexualized (vs. nonsexualized) and a great deal of evidence of photo modification (vs. low photo modification).
Study: NCT03008070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA337
Description: 1200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA337
Description: 800mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match
Study: NCT02932579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetominophen
Description: 650 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycontin/acetominophen
Description: 5mg Oxycontin, 325 mg acetominophen. This will be a rescue medication is the other three pain medications do not work.
Study: NCT01797354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy and hypnosis group
Study: NCT02555748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Study: NCT00326963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background ARVs
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfuvirtide [Fuzeon]
Description: 90mg sc bid
Study: NCT00706511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP (continuous positive airway pressure) treatment at home for 6 weeks
Study: NCT04268316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Behavioral Activation
Description: Participants will choose four activities to complete in virtual reality over the course of the week. These activities are video 360 and range from viewing animals, to viewing nature scenes, to traveling to a different location in the world, to viewing adrenaline-pumping activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Activation in real-life
Description: Participants will choose four pleasurable and/or mastery activities to complete over the course of the week in real life.
Study: NCT03677076

Intervention type: OTHER
Intervention: Ancillary/Correlative
Description: Collection of research blood and urine
Study: NCT03528083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchiolitis quality improvement
Description: Patients in the intervention group will undergo a quality improvement process to improve care quality for bronchiolitis at our hospital.